9. Pregnancy Test or FSH Level (Serum): For female participa nts of childbearing potential, a serum or urine pregnancy test, with sensitivity of at least 25 mIU/mL and assayed in a certified laboratory, will be performed on 2 occasions prior to starting study therapy, once at the start of screening and once at the b aseline visit immediately before investigational product administration. Pregnancy tests will also be repeated monthly during the Maintenance Treatment Perio d. Additional pregnancy tests may also be undertaken if requested by institutional review board/e thics committee (IRB/ECs) or if required by local regulations. Participants with confirmed positive pregnancy test(s) should not be dosed. For female participants who achieved postmenopausal status and have not experienced their menses for at least 12 consecutive months, a serum FSH test must be conducted at screening only to confirm a FSH level within the laboratory’s reference ranges. 10. Contraception Check: Male participants who are able to father children and female participants who are of childbearing p otential will need to affirm that they meet the criteria for correct use of 2 of the selected methods of contraception. The investigator or his or her designee will discuss with the participant the need to use 2 highly effective contraception methods cons istently and correctly and document such conversation in the participant’s chart. In addition, the investigator or his or he r designee will instruct PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 36Protocol Activity Maintenance Treatment Period * Study Month ** Month 9 Month 10Month 11Month 12Month 13Month 14Month 15Month 16Month 17Month 18 Month 19Month 20Month 21Month 22 and every month thereafter Visit Window (Days) ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 the participant to call immediately if one or both selected contraception methods are discontinued, or if pregnancy is known or suspected in the participant or the participant’s partner. 11.